NO330776B1 - Anvendelse av en adenovirus som har et funksjonelt thymidinkinase-gen, for fremstilling av et medikament for anvendelse i terapi av hjernetumor. - Google Patents

Anvendelse av en adenovirus som har et funksjonelt thymidinkinase-gen, for fremstilling av et medikament for anvendelse i terapi av hjernetumor. Download PDF

Info

Publication number
NO330776B1
NO330776B1 NO20012220A NO20012220A NO330776B1 NO 330776 B1 NO330776 B1 NO 330776B1 NO 20012220 A NO20012220 A NO 20012220A NO 20012220 A NO20012220 A NO 20012220A NO 330776 B1 NO330776 B1 NO 330776B1
Authority
NO
Norway
Prior art keywords
adenovirus
tumor
thymidine kinase
gene
patients
Prior art date
Application number
NO20012220A
Other languages
English (en)
Norwegian (no)
Other versions
NO20012220L (no
NO20012220D0 (no
Inventor
Seppo Yla-Herttuala
Anu-Maaria Sandmair
Sami Loimas
Matti Vapalahti
Original Assignee
Ark Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10842035&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO330776(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ark Therapeutics Ltd filed Critical Ark Therapeutics Ltd
Publication of NO20012220L publication Critical patent/NO20012220L/no
Publication of NO20012220D0 publication Critical patent/NO20012220D0/no
Publication of NO330776B1 publication Critical patent/NO330776B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20012220A 1998-11-06 2001-05-04 Anvendelse av en adenovirus som har et funksjonelt thymidinkinase-gen, for fremstilling av et medikament for anvendelse i terapi av hjernetumor. NO330776B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9824437.9A GB9824437D0 (en) 1998-11-06 1998-11-06 Gene therapy
PCT/EP1999/009017 WO2000028059A1 (en) 1998-11-06 1999-11-05 Adenovirus-mediated gene therapy

Publications (3)

Publication Number Publication Date
NO20012220L NO20012220L (no) 2001-05-04
NO20012220D0 NO20012220D0 (no) 2001-05-04
NO330776B1 true NO330776B1 (no) 2011-07-11

Family

ID=10842035

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012220A NO330776B1 (no) 1998-11-06 2001-05-04 Anvendelse av en adenovirus som har et funksjonelt thymidinkinase-gen, for fremstilling av et medikament for anvendelse i terapi av hjernetumor.

Country Status (18)

Country Link
US (1) US6579855B1 (cg-RX-API-DMAC7.html)
EP (1) EP1135513B2 (cg-RX-API-DMAC7.html)
JP (1) JP4733833B2 (cg-RX-API-DMAC7.html)
KR (1) KR20020013473A (cg-RX-API-DMAC7.html)
CN (1) CN1184321C (cg-RX-API-DMAC7.html)
AT (1) ATE341639T1 (cg-RX-API-DMAC7.html)
AU (1) AU749451B2 (cg-RX-API-DMAC7.html)
CA (1) CA2348624C (cg-RX-API-DMAC7.html)
CY (1) CY1106198T1 (cg-RX-API-DMAC7.html)
DE (1) DE69933468T3 (cg-RX-API-DMAC7.html)
DK (1) DK1135513T4 (cg-RX-API-DMAC7.html)
ES (1) ES2273521T5 (cg-RX-API-DMAC7.html)
GB (1) GB9824437D0 (cg-RX-API-DMAC7.html)
HU (1) HUP0104046A3 (cg-RX-API-DMAC7.html)
NO (1) NO330776B1 (cg-RX-API-DMAC7.html)
PL (1) PL193076B1 (cg-RX-API-DMAC7.html)
PT (1) PT1135513E (cg-RX-API-DMAC7.html)
WO (1) WO2000028059A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0910950D0 (en) 2009-06-24 2009-08-05 Ark Therapeutics Ltd Filtration
GB0916997D0 (en) * 2009-09-28 2009-11-11 Ark Therapeutics Ltd Combination therapy
US20130296407A1 (en) * 2011-01-18 2013-11-07 Ark Therapeutics, Ltd. Combination Therapy for Cancer
GB201100804D0 (en) * 2011-01-18 2011-03-02 Ark Therapeutics Ltd Drug combination
SG10201604810UA (en) 2012-02-07 2016-08-30 Global Bio Therapeutics Inc Compartmentalized method of nucleic acid delivery and compositions and uses thereof
US20160058888A1 (en) * 2013-05-08 2016-03-03 Gliotherapy Limited Treatment of Operable High-Grade Glioma With Sitimagene Ceradenovec Gene Therapy and Ganciclovir
CN105813579B (zh) 2013-08-08 2019-05-07 全球生物疗法有限公司 用于微创手术过程的夹具装置和其应用
DE102019000490A1 (de) 2019-01-23 2020-07-23 HAEMES Verwaltungsgesellschaft mbH Verwendung von Oligonukleotiden für die Behandlung von Tumoren
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
KR20230009430A (ko) 2020-05-12 2023-01-17 리제너론 파아마슈티컬스, 인크. 신규 il10 효능제 및 그의 사용 방법
CN117597365A (zh) 2021-05-04 2024-02-23 再生元制药公司 多特异性fgf21受体激动剂及其应用
AU2022314734A1 (en) 2021-07-19 2024-02-08 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
US12559576B2 (en) 2021-11-11 2026-02-24 Regeneron Pharmaceuticals, Inc. CD20-PD1 binding molecules and methods of use thereof
AU2024207005A1 (en) 2023-01-13 2025-08-28 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
CN121002062A (zh) 2023-01-13 2025-11-21 再生元制药公司 Fgfr3结合分子及其使用方法
IL322890A (en) 2023-02-28 2025-10-01 Regeneron Pharma Multispecific molecules containing an MHC-peptide complex containing an MHC domain and an antigenic peptide and a partially targeted immune cell antigen
WO2024233926A1 (en) 2023-05-10 2024-11-14 Regeneron Pharmaceuticals, Inc. Cd20-pd1 binding molecules and methods of use thereof
KR20260113057A (ko) 2023-11-14 2026-07-21 리제너론 파아마슈티컬스, 인크. 조작된 중쇄 가변 도메인 및 이의 용도
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0662441B2 (ja) * 1986-02-18 1994-08-17 花王株式会社 抗腫瘍物質徐放性製剤
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk

Also Published As

Publication number Publication date
US6579855B1 (en) 2003-06-17
AU749451B2 (en) 2002-06-27
PT1135513E (pt) 2006-12-29
DE69933468D1 (de) 2006-11-16
HUP0104046A3 (en) 2003-09-29
ES2273521T5 (es) 2011-12-28
CY1106198T1 (el) 2011-06-08
CN1325450A (zh) 2001-12-05
DE69933468T2 (de) 2007-01-11
CA2348624A1 (en) 2000-05-18
NO20012220L (no) 2001-05-04
NO20012220D0 (no) 2001-05-04
AU1385100A (en) 2000-05-29
EP1135513B1 (en) 2006-10-04
ATE341639T1 (de) 2006-10-15
JP4733833B2 (ja) 2011-07-27
PL349489A1 (en) 2002-07-29
PL193076B1 (pl) 2007-01-31
HUP0104046A2 (hu) 2002-01-28
EP1135513B2 (en) 2011-08-10
DE69933468T3 (de) 2012-01-19
KR20020013473A (ko) 2002-02-20
CN1184321C (zh) 2005-01-12
DK1135513T4 (da) 2011-11-21
DK1135513T3 (da) 2006-11-27
WO2000028059A1 (en) 2000-05-18
GB9824437D0 (en) 1999-01-06
ES2273521T3 (es) 2007-05-01
CA2348624C (en) 2012-07-31
JP2002529097A (ja) 2002-09-10
EP1135513A1 (en) 2001-09-26

Similar Documents

Publication Publication Date Title
AU749451B2 (en) Adenovirus-mediated gene therapy
US6979677B1 (en) Inhibition of vascular smooth muscle cell proliferation
US11951183B2 (en) Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
US6632427B1 (en) Adenoviral-vector-mediated gene transfer into medullary motor neurons
EP0755454B1 (en) Aav-mediated delivery of dna to cells of the nervous system
AU708870B2 (en) Gene therapy using ovine adenoviral vectors
US20020187127A1 (en) Methods of increasing distribution of nucleic acids
US20020091094A1 (en) Glutamic acid decarboxylase (GAD) based delivery system
JP2002516295A (ja) Aavベクターの対流増加送達
CA2216878A1 (en) Viral vectors and their use for treating hyperproliferative disorders, in particular restenosis
US6410011B1 (en) Gene therapy for restenosis using an adenoviral vector
EP1478236B1 (en) Targeted retrograde gene delivery to motor neurons
EP4347791A1 (en) Drug for genetic and gene-cell-based therapy
WO2003092598A2 (en) Treatment for pompe disease
Jani et al. Modulation of cell-mediated immunity prolongs adenovirus-mediated transgene expression in sciatic nerve
US7405284B2 (en) Reducing cellular dysfunction caused by mitochondrial gene mutations
Shimizu et al. Infectious retrovirus is inactivated by serum but not by cerebrospinal fluid or fluid from tumor bed in patients with malignant glioma
HUP0104032A2 (hu) Új rendszer transzgén kifejeződés szabályozására
MXPA01004410A (es) Terapia de gen mediada por adenovirus
Lowenstein et al. Gene therapy for neurological disorders
Murphy et al. Gene therapy approaches to Duchenne muscular dystrophy

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees